Address: Friedrichstraße 149, 10117 Berlin,Germany
Tel: 0049 (0) 30 206 582 – 0
Web: http://www.shire.de/
Founded in 1986, Shire is a fast-growing global specialty biopharmaceutical company with 2008 revenues of $3 billion and over 3,500 employees worldwide. A global leader working to meet the needs of the specialist physician and the patients they serve, Shire today has a presence in 23 countries and medicines available in nearly 40 countries.
Shire’s operation is structured in two complementary businesses – Human Genetic Therapies (HGT), and Specialty Pharmaceuticals – that are each supported by various corporate functions. The HGT team specializes in researching, developing, and commercializing therapies for the treatment of rare genetic diseases caused by protein deficiencies. Shire’s Specialty Pharmaceuticals team is made up currently of three business units – ADHD, GI, and Emerging Products. This team also oversees many other marketed medicines approved to help people around the world.
Shire focuses on the therapeutic areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI), and genetic disorders.
The acquisition of Jerini has to be one of the biggest milestones for Shire Deutschland in its recent history. How have the synergies developed between the two companies, and how…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
